Pediatric patients with leukemia have longer stay if admitted on weekend
the ONA take:
According to a new study published in The Journal of the American Medical Association Pediatrics, pediatric patients with newly diagnosed leukemia who were admitted to the hospital on the weekend had a longer length of stay, a small delay in initiating chemotherapy, and a greater risk for respiratory failure; however, these patients did not have an increased risk for death.
Researchers analyzed data from the Pediatric Health Information System database from 1999 to 2011 and identified 10,720 pediatric patients with newly diagnosed acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). Of those, 16.7% were admitted to the hospital on the weekend. Patients admitted on the weekend had a 1.4-day longer length of stay, a 0.36-day longer time to chemotherapy initiation, and an increased risk for respiratory failure.
Researchers suggest that hospitals should consider the need to admit pediatric patients with leukemia and the clinical resources available on the weekend, and determine whether available resources are allocated to those patients who require comprehensive care. A longer length of stay and an increased risk for respiratory failure increase the cost of admission and may increase the risk for readmission.
Weekend admission for pediatric patients with leukemia associated with a longer length of stay.
Leukemia is a common childhood cancer that accounts for about 30 percent of all pediatric cancer diagnoses. Previous research has indicated an increased risk of death in adults with leukemia whose first admission was on a weekend. But there has been little investigation of weekend admissions for pediatric leukemia patients.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|